ArticleJournal of paediatrics and child health2026
Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis.
Article in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimMonosymptomatic nocturnal enuresis (MNE) significantly impacts many children, with substantial patient groups refractory to conventional first-line treatments. Intravesical Botox is used for various refractory functional voiding disorders in children, but its efficacy in MNE has not been widely established. This study aimed to determine the efficacy of intravesical Botox in children with refractory monosymptomatic nocturnal enuresis.
methodsA retrospective analysis was conducted of 22 children with MNE (median age 11 years; 19 males) treated with intravesical Botox injection over a 6 year period. All participants had previously failed desmopressin, and the majority had trialled an enuresis alarm and oxybutynin. Each child received 200iU of Botox injected into the detrusor muscle. Treatment outcomes were classified as complete (100% reduction in wet nights), partial (50%-99% reduction), or no response (0%-49% reduction).
resultsPrior to treatment, median number of wet nights was six per week. Following the final injection, complete response was observed in 8 of 22 (36%) children, partial response in 7 of 22 (32%), and no response in 7 of 22 (32%). Median reduction in wet nights was 2.5 per week. Median duration of response for those experiencing relapse was 11 months. No intra-operative complications occurred. Post-operative complications were mild and self-resolving, limited to transient haematuria/pain and dysuria in isolated cases, with no instances of urinary tract infection or retention.
conclusionsIntravesical Botox injection is an effective, well-tolerated treatment option for children with refractory monosymptomatic nocturnal enuresis, demonstrating a sustained response in a significant proportion of patients. This intervention presents a valuable option for treating this multi-faceted condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.